Clinical Trial Search

Primary: Percentage of Subjects With Antigenically Matched Strain-specific Hemagglutination Inhibition (HAI)Seroconversion Following the First Dose - H1N1 /wt A/New…

Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants

Primary: Best Overall Response — 0; 1; 15; 11 participants

Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4)Applied for up to 84 Days — 18; 53; 71 participants

Primary: Response Rate Per Independent Central Review — 32 of Patients who Responded

Primary: The Number of Study Participants Who Safely Tolerated Somatokine — 6; 9 participants

Primary: Number of Subjects Who Complete the Trial — 17; 16; 16; 17 participants

Primary: Change From Baseline of the Apoptotic Index During Treatment Phase — 6.2; 4.2 Percentage of positive cells — p=.394

Primary: Number of Responders With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders) — 12; 7; 5; 15 participants

Primary: Best Overall Response — 0; 1; 9; 23 Participants

Primary: Complete Cure of Onychomycosis at Week 48. — 8; 20; 15; 7 Participants — p=0.005

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 56 — 0.18; 0.42 copies/mL on log scale

Primary: Number of Patients With Venous Thromboembolism at Week 4 — 0 Participants

Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 — .46; 5.71; 6.73; 7.45 Percent Change from Baseline — p=<0.0001

Primary: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12 — 2.4; 3.4; -.8 Percent Change from Baseline